{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:25:36Z","timestamp":1787761536406,"version":"build-2784847793"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,1,14]],"date-time":"2014-01-14T00:00:00Z","timestamp":1389657600000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study was a comparative investigation of the clinical efficacy and safety of intramuscular (IM) olanzapine, IM haloperidol, and IM levomepromazine in acute agitated patients with schizophrenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The subjects were 122 inpatients. Their clinical symptoms were assessed using Positive and Negative Syndrome Scale Excited Component (PANSS\u2010EC), PANSS, and Agitation\u2013Calmness Evaluation Scale, and their safety were assessed using the Abnormal Involuntary Movement Scale, Barnes Akathisia Rating Scale (BARS), and Drug\u2010induced Extrapyramidal Symptoms Scale (DIEPSS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean changes from baseline on the PANSS\u2010EC, Agitation\u2013Calmness Evaluation Scale, Abnormal Involuntary Movement Scale, BARS, and DIEPSS scores were significantly better in both IM olanzapine and IM levomepromazine than in IM haloperidol. Of these, the mean changes from baseline on the BARS and DIEPSS scores were significantly better in IM olanzapine than in IM levomepromazine. The mean change from baseline on the PANSS positive score was significantly better in both IM olanzapine and IM haloperidol than in IM levomepromazine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The results of this study suggest the possibility that the anti\u2010agitation effects of IM olanzapine and IM levomepromazine are more rapid than those of IM haloperidol. No worsening of EPS was observed. Our results also suggest that compared with IM levomepromazine, IM olanzapine is safer and affords greater improvement in symptoms. Copyright \u00a9 2014 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.2376","type":"journal-article","created":{"date-parts":[[2014,1,15]],"date-time":"2014-01-15T06:27:55Z","timestamp":1389767275000},"page":"83-88","source":"Crossref","is-referenced-by-count":20,"title":["A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia"],"prefix":"10.1002","volume":"29","author":[{"given":"Hidenobu","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of Psychiatry Suzuki Clinic  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Gen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Seimo Hospital  Gunma Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Course of Specialized Clinical Science Tokai University School of Medicine [Y.T.]  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,14]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/00131746-200511001-00002"},{"key":"e_1_2_8_3_1","volume-title":"Practice Guidelines for the Treatment of Patients with Schizophrenia","author":"American Psychiatric Association","year":"2004"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"e_1_2_8_5_1","first-page":"305","article-title":"Examination of the safety, tolerance and pharmacokinetics of intramuscular (IM) olanzapine compared to oral olanzapine in healthy subjects","volume":"36","author":"Bergstrom RF","year":"1999","journal-title":"Schizophr Res"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1998.tb03827.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1176\/ps.50.12.1553"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200023030-00004"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199509000-00014"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0839-9"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079904X12708"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979313"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181db8715"},{"key":"e_1_2_8_14_1","first-page":"11","volume-title":"Commentary on the DIEPSS and Guide to Its Usage","author":"Inada T","year":"1996"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/16.3.537"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1989.01810100056011"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-440X(97)90031-6"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937060-00001"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318253a2fe"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1225"},{"key":"e_1_2_8_22_1","first-page":"477","article-title":"A study examining pharmacokinetics of rapid acting intra\u2010muscular olanzapine in Japanese agitated patients with schizophrenia\u2010rapid acting intra\u2010muscular olanzapine phase Ib study","volume":"11","author":"Ono H","year":"2008","journal-title":"Jpn Clin Psychopharmacol"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.01.008"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2010.04.005"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02035-3"},{"key":"e_1_2_8_26_1","first-page":"166","volume-title":"Handbook of Psychiatric Measures","author":"Rush JA","year":"2000"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n1204"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198208000-00008"},{"key":"e_1_2_8_29_1","first-page":"5","article-title":"Common treatment goals of antipsychotics: acute treatment","volume":"59","author":"Sharif ZA","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_8_30_1","first-page":"CD007779","article-title":"Levomepromazine for schizophrenia","volume":"10","author":"Sivaraman P","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1218"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.5811\/westjem.2011.9.6866"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.2376","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T23:35:51Z","timestamp":1696462551000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1002\/hup.2376"],"URL":"https:\/\/doi.org\/10.1002\/hup.2376","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}